What is Ozempic?

Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.

What is the Ozempic controversy?

The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.

Ozempic Patent Details

Ozempic is a drug owned by Novo Nordisk Inc. It is protected by 39 US drug patents filed from 2018 to 2026. Out of these, 19 drug patents are active and 20 have expired. Ozempic's patents have been open to challenges since 05 December, 2021. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 17, 2041. Details of Ozempic's patents and their expiration are given in the table below.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ozempic's patents.

Latest Legal Activities on Ozempic's Patents

Given below is the list of recent legal activities going on the following patents of Ozempic.

Activity	Date	Patent Number
Critical Events This Week
Expire Patent	15 Dec, 2025	US8579869
Maintenance Fee Reminder Mailed	03 Nov, 2025	US8672898
Payment of Maintenance Fee, 12th Year, Large Entity	25 Sep, 2025	US8684969
Payment of Maintenance Fee, 4th Year, Large Entity	25 Sep, 2025	US11311679
Maintenance Fee Reminder Mailed	30 Jun, 2025	US8579869
Payment of Maintenance Fee, 8th Year, Large Entity	20 Jun, 2025	US9861757
Recordation of Patent Grant Mailed	20 May, 2025	US12295988
Patent eGrant Notification	13 May, 2025	US12295988
Mail Patent eGrant Notification	13 May, 2025	US12295988
Patent Issue Date Used in PTA Calculation	13 May, 2025	US12295988

While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Ozempic and ongoing litigations to help you estimate the early arrival of Ozempic generic.

Ozempic's Litigations

Ozempic been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jul 22, 2020, against patent number US8114833. The petitioner Pfizer Inc., challenged the validity of this patent, with Novo Nordisk A/S as the respondent. Click below to track the latest information on how companies are challenging Ozempic's patents.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
Live updates
US10335462	March, 2023	Terminated-Settled (10 Jan, 2025)	Novo Nordisk A/S	Mylan Pharmaceuticals Inc. et al.
US10335462	October, 2023	Terminated-Settled (10 Jan, 2025)	Novo Nordisk A/S	DR. REDDY'S LABORATORIES, INC. et al.
US10335462	November, 2023	Terminated-Settled (10 Jan, 2025)	Novo Nordisk A/S	Sun Pharmaceutical Industries Ltd. et al.
US10335462	March, 2024	Terminated-Settled (10 Jan, 2025)	Novo Nordisk A/S	Apotex Inc. et al.
US8129343	March, 2023	Institution Denied (02 Oct, 2023)	Novo Nordisk A/S	Mylan Pharmaceuticals Inc. et al.
US8536122	March, 2023	Institution Denied (02 Oct, 2023)	Novo Nordisk A/S	Mylan Pharmaceuticals Inc. et al.
US8114833	March, 2022	Terminated-Settled (08 Sep, 2022)	Novo Nordisk A/S	Fresenius Kabi USA, LLC
US8114833	December, 2019	Terminated-Settled (21 Jun, 2021)	Novo Nordisk A/S et al.	Pfizer Inc. et al.
US8114833	July, 2020	Terminated-Settled (21 Jun, 2021)	Novo Nordisk A/S	Pfizer Inc.

FDA has granted some exclusivities to Ozempic. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Ozempic, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Ozempic.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Download Report

Several oppositions have been filed on Ozempic's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Ozempic's generic, the next section provides detailed information on ongoing and past EP oppositions related to Ozempic patents.

Ozempic's Oppositions Filed in EPO

Ozempic has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 23, 2006, by Owen Mumford Limited. This opposition was filed on patent number EP02726984A. Click below to reveal the latest opposition data.

Application	Filing Date	Opposition Party	Legal Status
Live updates
EP02726984A	NA	Genentech, Inc.	Patent maintained as amended
EP13737808A	Jan, 2021	Galenicum Health S.L.U.	Granted and Under Opposition
EP13737808A	Jan, 2021	Generics [UK] Limited	Granted and Under Opposition
EP13737808A	Jan, 2021	Teva Pharmaceutical Industries LTD.	Granted and Under Opposition
EP17204363A	Dec, 2020	Galenicum Health S.L.U.	Granted and Under Opposition
EP17204363A	Dec, 2020	Generics (U.K.) Limited	Granted and Under Opposition
EP17204363A	Dec, 2020	Hexal AG	Granted and Under Opposition
EP17204363A	Dec, 2020	Teva Pharmaceutical Industries Ltd.	Granted and Under Opposition
EP17196501A	Dec, 2019	Generics (U.K.) Limited	Granted and Under Opposition
EP17196501A	Dec, 2019	Hoffmann Eitle	Granted and Under Opposition
EP17196501A	Dec, 2019	Dr. Reddy's Laboratories Limited	Granted and Under Opposition
EP17196501A	Dec, 2019	Galenicum Health S.L.U.	Granted and Under Opposition
EP17196501A	Dec, 2019	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP14721834A	May, 2019	Sanofi	Granted and Under Opposition
EP14721834A	May, 2019	Hexal AG	Granted and Under Opposition
EP14721834A	May, 2019	Galenicum Health S.L.U.	Granted and Under Opposition
EP14721834A	May, 2019	Lederer & Keller Patentanwälte Partnerschaft mbB	Granted and Under Opposition
EP14721834A	May, 2019	Generics (U.K.) Limited	Granted and Under Opposition
EP14721834A	May, 2019	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP11805824A	Sep, 2018	Galenicum Health S.L.	Granted and Under Opposition
EP11805824A	Sep, 2018	Generics (U.K.) Limited	Granted and Under Opposition
EP11805824A	Sep, 2018	Hexal AG	Granted and Under Opposition
EP11805824A	Sep, 2018	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP04797453A	Aug, 2018	Uexküll & Stolberg Partnerschaft von Patent- und Rechtsanwälten mbB	Opposition rejected
EP04797453A	Aug, 2018	Wittkopp, Alexander	Opposition rejected
EP04797453A	Aug, 2018	Teva Pharmaceutical Industries Ltd	Opposition rejected
EP04797453A	Aug, 2018	Generics (U.K.) Limited	Opposition rejected
EP04797453A	Aug, 2018	Sandoz AG	Opposition rejected
EP04797453A	Aug, 2018	Fresenius Kabi Deutschland GmbH	Opposition rejected
EP06701034A	Jan, 2018	Schwöbel, Thilo	Opposition rejected
EP06754730A	Dec, 2011	Ypsomed AG	Patent maintained as amended
EP06754730A	Nov, 2011	WMC Matthes Consulting	Patent maintained as amended
EP06725149A	May, 2011	AMYLIN PHARMACEUTICALS, INC.	Opposition rejected
EP06762643A	Jul, 2010	Sanofi-Aventis Deutschland GmbH	Patent maintained as amended
EP05796880A	Jul, 2010	Ypsomed AG	Granted and Under Opposition
EP05796880A	Jul, 2010	Stöckeler, Ferdinand	Granted and Under Opposition
EP05796880A	Jul, 2010	Ferring International Center S.A.	Granted and Under Opposition
EP05796880A	Jul, 2010	OWEN MUMFORD LIMITED	Granted and Under Opposition
EP05796880A	Jul, 2010	COPERNICUS sp. zo.o.	Granted and Under Opposition
EP05796880A	Jul, 2010	Genentech, Inc.	Granted and Under Opposition
EP06121820A	May, 2010	SANOFI-AVENTIS DEUTSCHLAND GMBH	Opposition rejected
EP02726984A	Mar, 2006	TecPharma Licensing AG	Patent maintained as amended
EP02726984A	Feb, 2006	OWEN MUMFORD LIMITED	Patent maintained as amended

US patents provide insights into the exclusivity only within the United States, but Ozempic is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Ozempic's family patents as well as insights into ongoing legal events on those patents.

Ozempic's Family Patents

Ozempic has patent protection in a total of 38 countries. It's US patent count contributes only to 19.0% of its total global patent coverage. Click below to unlock the full patent family tree for Ozempic.

Unlock Global Patents

Clinical Trials

Title	Lead Sponsor	Collaborators	Status	Phases
Latest Clinical Trials
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes	Novo Nordisk A/S	NA	ACTIVE NOT RECRUITING (Sep 1, 2026)	PHASE3
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)	Novo Nordisk A/S	NA	ACTIVE NOT RECRUITING (Sep 1, 2026)	PHASE3
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver	Boehringer Ingelheim	NA	ACTIVE NOT RECRUITING (Sep 1, 2026)	PHASE1
Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)	Vanderbilt University Medical Center	NA	ACTIVE NOT RECRUITING (Sep 1, 2026)	PHASE2
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight	Novo Nordisk A/S	NA	ACTIVE NOT RECRUITING (Sep 1, 2026)	PHASE3
The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial	Odense University Hospital	NA	ACTIVE NOT RECRUITING (Sep 1, 2026)	PHASE2
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo	Novo Nordisk A/S	NA	COMPLETED (Sep 1, 2026)	PHASE2
Semaglutide for Post-Smoking Cessation Weight Management	The University of Texas Health Science Center, Houston	NA	RECRUITING (Sep 1, 2026)	PHASE2
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor	Novo Nordisk A/S	NA	COMPLETED (Sep 1, 2026)	PHASE3
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin	Novo Nordisk A/S	NA	COMPLETED (Sep 1, 2026)	PHASE3
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both	Novo Nordisk A/S	NA	COMPLETED (Sep 1, 2026)	PHASE3
Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV	University of Maryland, Baltimore	NA	ACTIVE NOT RECRUITING (Sep 1, 2026)	PHASE2
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy	Novo Nordisk A/S	NA	COMPLETED (Sep 1, 2026)	PHASE2
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide	Eli Lilly and Company	NA	RECRUITING (Sep 1, 2026)	PHASE2
Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus	University Health Network, Toronto	NA	NOT YET RECRUITING (Sep 1, 2026)	PHASE2, PHASE3
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism	Novo Nordisk A/S	NA	RECRUITING (Sep 1, 2026)	PHASE1
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet	Novo Nordisk A/S	NA	ACTIVE NOT RECRUITING (Sep 1, 2026)	PHASE1
Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)	Rezera (formerly NodThera Limited)	NA	COMPLETED (Sep 1, 2026)	PHASE2
Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)	Yale University	NA	ACTIVE NOT RECRUITING (Sep 1, 2026)	PHASE1
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes	Novo Nordisk A/S	NA	RECRUITING (Sep 1, 2026)	PHASE3
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes	Novo Nordisk A/S	NA	RECRUITING (Sep 1, 2026)	PHASE2
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss	Veru Inc.	NA	ACTIVE NOT RECRUITING (Sep 1, 2026)	PHASE2
A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity	Novo Nordisk A/S	NA	ACTIVE NOT RECRUITING (Sep 1, 2026)	PHASE2
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)	The United Bio-Technology (Hengqin) Co., Ltd.	NA	RECRUITING (Sep 1, 2026)	PHASE3
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes	Novo Nordisk A/S	NA	RECRUITING (Sep 1, 2026)	PHASE2
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight	Novo Nordisk A/S	NA	RECRUITING (Sep 1, 2026)	PHASE3
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight	Novo Nordisk A/S	NA	RECRUITING (Sep 1, 2026)	PHASE3
Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus	University of Massachusetts, Worcester	NA	NOT YET RECRUITING (Sep 1, 2026)	PHASE2, PHASE3
A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)	Beijing QL Biopharmaceutical Co.,Ltd	NA	NOT YET RECRUITING (Sep 1, 2026)	PHASE2
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema	Novo Nordisk A/S	NA	NOT YET RECRUITING (Sep 1, 2026)	PHASE3
Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial	Zagazig University	NA	COMPLETED (Sep 1, 2026)	PHASE3
Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes	Zagazig University	NA	COMPLETED (Sep 1, 2026)	PHASE3
A Study Comparing the Effects of BGM0504 Injection and Semaglutide Injection on Obese Subjects.	Second Affiliated Hospital of Soochow University	NA	COMPLETED (Sep 1, 2026)	PHASE2
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss	Alveus Therapeutics, Inc.	NA	RECRUITING (Sep 1, 2026)	PHASE2
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity	Novo Nordisk A/S	NA	COMPLETED (Aug 1, 2026)	PHASE3
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight	Novo Nordisk A/S	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE3
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels	Novo Nordisk A/S	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE3
A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease	Novo Nordisk A/S	NA	COMPLETED (Aug 1, 2026)	PHASE3
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin	Eli Lilly and Company	NA	COMPLETED (Aug 1, 2026)	PHASE3
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation	Regeneron Pharmaceuticals	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE2
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity	Novo Nordisk A/S	NA	COMPLETED (Aug 1, 2026)	PHASE1
Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth	Children's Hospital Los Angeles	NA	RECRUITING (Aug 1, 2026)	PHASE3
A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes	Novo Nordisk A/S	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE1
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight	Novo Nordisk A/S	NA	RECRUITING (Aug 1, 2026)	PHASE3
A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes	Novo Nordisk A/S	NA	COMPLETED (Aug 1, 2026)	PHASE3
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes	Kailera	NA	RECRUITING (Aug 1, 2026)	PHASE3
A Study of CS060380 Tablets in Patients With MASH and Obesity	Cascade Pharmaceuticals, Inc	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE2
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight	Novo Nordisk A/S	NA	RECRUITING (Aug 1, 2026)	PHASE3
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide	Novo Nordisk A/S	NA	NOT YET RECRUITING (Aug 1, 2026)	PHASE3
HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide	Vanderbilt University Medical Center	NA	NOT YET RECRUITING (Aug 1, 2026)	PHASE2
A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity	Novo Nordisk A/S	NA	RECRUITING (Aug 1, 2026)	PHASE1
Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes	Yale University	NA	NOT YET RECRUITING (Aug 1, 2026)	PHASE1
Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus	Shanghai Minwei Biotechnology Co., Ltd	NA	RECRUITING (Aug 1, 2026)	PHASE2
A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes	Novo Nordisk A/S	NA	COMPLETED (Jul 1, 2026)	PHASE3
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)	Novo Nordisk A/S	NA	COMPLETED (Jul 1, 2026)	PHASE3
Pharmacogenetics of Response to GLP1R Agonists	University of Maryland, Baltimore	NA	RECRUITING (Jul 1, 2026)	PHASE1
Sit Less, Interact and Move More (SLIMM) 2 Study	Srinvasan Beddhu	NA	RECRUITING (Jul 1, 2026)	PHASE2
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor	Novo Nordisk A/S	NA	COMPLETED (Jul 1, 2026)	PHASE3
COMMETS- Combination MCI Metabolic Syndrome	Rutgers, The State University of New Jersey	NA	RECRUITING (Jul 1, 2026)	PHASE2
Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment	Yale University	NA	RECRUITING (Jul 1, 2026)	PHASE2
Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents	University of Colorado, Denver	NA	RECRUITING (Jul 1, 2026)	PHASE1
A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes	Fujian Shengdi Pharmaceutical Co., Ltd.	NA	COMPLETED (Jul 1, 2026)	PHASE3
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus	Eli Lilly and Company	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE1
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term	Novo Nordisk A/S	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes	Hoffmann-La Roche	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE2
A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes	Novo Nordisk A/S	NA	WITHDRAWN (Jul 1, 2026)	PHASE2
A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight	Novo Nordisk A/S	NA	WITHDRAWN (Jul 1, 2026)	PHASE3
A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers	Daewoong Pharmaceutical Co. LTD.	NA	RECRUITING (Jul 1, 2026)	PHASE1
A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities	Verdiva Bio Dev Limited	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE2
Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants	Terrestrial Bio, Inc.	NA	RECRUITING (Jul 1, 2026)	PHASE1
A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity	Antag Therapeutics	NA	RECRUITING (Jul 1, 2026)	PHASE2
Semaglutide for Low Back Pain	Washington University School of Medicine	NA	NOT YET RECRUITING (Jul 1, 2026)	PHASE2
Myocardial Metabolic Flux in Pulmonary Arterial Hypertension	Imperial College London	NA	NOT YET RECRUITING (Jul 1, 2026)	PHASE2
A Study of BGM0504 in Early T2DM With Obesity	BrightGene Bio-Medical Technology Co., Ltd.	NA	RECRUITING (Jul 1, 2026)	PHASE3
Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults	Lumos Pharma	NA	NOT YET RECRUITING (Jul 1, 2026)	PHASE2
Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant	University of Virginia	NA	RECRUITING (Jun 1, 2026)	PHASE2
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity	Innovent Biologics (Suzhou) Co. Ltd.	NA	COMPLETED (Jun 1, 2026)	PHASE3
A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)	Novo Nordisk A/S	NA	COMPLETED (Jun 1, 2026)	PHASE3
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)	Eli Lilly and Company	NA	COMPLETED (Jun 1, 2026)	PHASE3
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy	Biomea Fusion Inc.	NA	RECRUITING (Jun 1, 2026)	PHASE2
MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial	Eccogene	NA	ACTIVE NOT RECRUITING (Jun 1, 2026)	PHASE2
BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity	Carnot Laboratories	NA	NOT YET RECRUITING (Jun 1, 2026)	PHASE3
BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes	Carnot Laboratories	NA	NOT YET RECRUITING (Jun 1, 2026)	PHASE3
A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes	Novo Nordisk A/S	NA	COMPLETED (May 1, 2026)	PHASE3
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)	Novo Nordisk A/S	NA	COMPLETED (May 1, 2026)	PHASE3
A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes	Novo Nordisk A/S	NA	COMPLETED (May 1, 2026)	PHASE3
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes	University of Washington	NA	RECRUITING (May 1, 2026)	PHASE2
A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight	Novo Nordisk A/S	NA	COMPLETED (May 1, 2026)	PHASE1
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight	Novo Nordisk A/S	NA	COMPLETED (May 1, 2026)	PHASE3
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity	Boehringer Ingelheim	NA	ACTIVE NOT RECRUITING (May 1, 2026)	PHASE1
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）	Innovent Biologics (Suzhou) Co. Ltd.	NA	ACTIVE NOT RECRUITING (May 1, 2026)	PHASE3
UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study	The United Bio-Technology (Hengqin) Co., Ltd.	NA	COMPLETED (May 1, 2026)	PHASE2
GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV	Vanderbilt University Medical Center	NA	RECRUITING (May 1, 2026)	PHASE2
Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder	Anders Fink-Jensen, MD, DMSci	NA	RECRUITING (May 1, 2026)	PHASE2
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)	Novo Nordisk A/S	NA	RECRUITING (May 1, 2026)	PHASE1
Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients	Ole Lander Svendsen	NA	RECRUITING (May 1, 2026)	PHASE3
A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity	Novo Nordisk A/S	NA	NOT YET RECRUITING (May 1, 2026)	PHASE1
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus	AstraZeneca	NA	RECRUITING (May 1, 2026)	PHASE3
Effects of Semaglutide in HIV-Associated Lipohypertrophy	Case Western Reserve University	NA	ACTIVE NOT RECRUITING (Apr 1, 2026)	PHASE2
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)	Novo Nordisk A/S	NA	COMPLETED (Apr 1, 2026)	PHASE3
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease	Yale University	NA	ACTIVE NOT RECRUITING (Apr 1, 2026)	PHASE2
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)	Novo Nordisk A/S	NA	COMPLETED (Apr 1, 2026)	PHASE3
A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)	Novo Nordisk A/S	NA	COMPLETED (Apr 1, 2026)	PHASE3
A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight	Novo Nordisk A/S	NA	COMPLETED (Apr 1, 2026)	PHASE3
Feasibility of Semaglutide in Advanced Lung Disease	University of Pennsylvania	NA	RECRUITING (Apr 1, 2026)	PHASE1, PHASE2
A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range	Novo Nordisk A/S	NA	COMPLETED (Apr 1, 2026)	PHASE3
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)	Eli Lilly and Company	NA	ACTIVE NOT RECRUITING (Apr 1, 2026)	PHASE3
A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes	Novo Nordisk A/S	NA	COMPLETED (Mar 1, 2026)	PHASE2
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction	Mayo Clinic	NA	ENROLLING BY INVITATION (Mar 1, 2026)	PHASE2
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise	Novo Nordisk A/S	NA	COMPLETED (Mar 1, 2026)	PHASE3
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight	Novo Nordisk A/S	NA	NOT YET RECRUITING (Mar 1, 2026)	PHASE3
A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes	Novo Nordisk A/S	NA	RECRUITING (Sep, 2024)	PHASE3
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice	Novo Nordisk A/S	NA	COMPLETED (Sep, 2024)
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)	Novo Nordisk A/S	NA	ACTIVE NOT RECRUITING (Sep, 2024)	PHASE3
Semaglutide Treatment for Hyperglycaemia After Renal Transplantation	Rigshospitalet, Denmark	Aarhus University Hospital, Odense University Hospital	RECRUITING (Jun, 2024)	PHASE4
Semaglutide in CFRD	University of Minnesota	Cystic Fibrosis Foundation	RECRUITING (Jun, 2024)	PHASE2, PHASE3
A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy	Novo Nordisk A/S	NA	ENROLLING BY INVITATION (Oct, 2023)
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People	Novo Nordisk A/S	NA	COMPLETED (Jun, 2023)	PHASE1
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes	Novo Nordisk A/S	NA	COMPLETED (Jul, 2022)	PHASE3
Real-world Health Outcomes in Canadian Patients Using Semaglutide	LMC Diabetes & Endocrinology Ltd.	NA	COMPLETED (Feb, 2020)
A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes	Novo Nordisk A/S	NA	COMPLETED (Aug, 2018)	PHASE1

Generic Launch

About Ozempic

Ozempic is a drug owned by Novo Nordisk Inc. It is used for treating Type 2 diabetes as an adjunct to diet and exercise to improve glycemic control in adults. Ozempic uses Semaglutide as an active ingredient. Ozempic was launched by Novo Nordisk in 2026.